Jim Weissman
Former, COO/CBO Dicerna Pharmaceuticals Jim Weissman has more than 30 years’ experience in the life sciences industry including business and corporate development, general management, marketing, M&A, new product planning and development, and other operating activities.
About this speaker
Jim Weissman has more than 30 years’ experience in the life sciences industry including business and corporate development, general management, marketing, M&A, new product planning and development, and other operating activities. Jim is currently the principal of JBW Consulting LLC, a biotech consulting firm specializing in business and corporate development and an independent board member of Cerberus Therapeutics and Telesis Bio.
Previously, Jim was EVP/COO/CBO of Dicerna Pharmaceuticals (acquired by Novo Nordisk 2021) where he led a series of business development deals with industry leaders including Alexion, Alnylam, Boehringer Ingelheim, Lilly, Novo Nordisk, and Roche. Prior to Dicerna, Jim was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new product planning, and strategic planning. Prior to MannKind, Jim held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, Japan. Prior to Pfizer, Jim held commercial and leadership positions in Pharmacia Biotech in the USA, Sweden, Japan, and the UK.
Jim holds a Bachelor of Science degree from Bates College.
